Adly Amira A, Ismail Eman A, Andrawes Nevine G, Mahmoud Mai M, Eladawy Rasha
Department of Pediatric, Faculty of Medicine, Ain Shams University, Egypt.
Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Egypt.
Cytokine. 2016 Mar;79:52-8. doi: 10.1016/j.cyto.2015.12.022. Epub 2016 Jan 5.
Sickle cell disease (SCD) is characterized by chronic inflammation due to ischemic tissue damage, accentuated during acute complications. Fas and its ligand (FasL) are members of tumor necrosis factor receptor superfamily and a major pathway for induction of apoptosis. Fas/FasL interactions may be related to augmentation of inflammatory response. We assessed the levels of sFas and sFasL in 35 children and adolescents with SCD compared with 35 healthy controls in relation to hemolysis, iron overload, sickle vasculopathy including kidney disease.
SCD patients, in steady state and asymptomatic for pulmonary hypertension, were studied stressing on hydroxyurea therapy, serum ferritin, urinary albumin creatinine ratio (UACR), high-sensitivity C-reactive protein (hs-CRP) and sFas/sFasL levels.
sFas/sFasL ratio was significantly higher in patients compared with controls. sFas/sFasL ratio was elevated in patients with pulmonary hypertension, nephropathy and those who had history of frequent sickling crisis or serum ferritin ⩾2500. SCD patients treated with hydroxyurea had lower sFas/sFasL ratio than untreated patients. sFas/sFasL ratio was positively correlated to transfusion index, white blood cells, hs-CRP, serum ferritin and UACR. The cutoff value of sFas/sFasL at 8.75pg/mL could differentiate SCD patients with and without nephropathy while the cutoff value at 22pg/mL could differentiate SCD patients with and without pulmonary hypertension risk with high sensitivity and specificity.
sFas/sFasL ratio may be considered as a marker for vascular dysfunction in SCD patients and is related to inflammation, iron overload and albuminuria level. Thus, it may be a reliable method to assess renal impairment in SCD.
镰状细胞病(SCD)的特征是由于缺血性组织损伤导致慢性炎症,在急性并发症期间会加重。Fas及其配体(FasL)是肿瘤坏死因子受体超家族的成员,也是诱导细胞凋亡的主要途径。Fas/FasL相互作用可能与炎症反应增强有关。我们评估了35例儿童和青少年SCD患者与35例健康对照者的可溶性Fas(sFas)和可溶性FasL(sFasL)水平,同时分析了溶血、铁过载、包括肾病在内的镰状血管病变情况。
对处于稳定状态且无肺动脉高压症状的SCD患者进行研究,重点关注羟基脲治疗、血清铁蛋白、尿白蛋白肌酐比值(UACR)、高敏C反应蛋白(hs-CRP)以及sFas/sFasL水平。
与对照组相比,患者的sFas/sFasL比值显著更高。肺动脉高压患者、肾病患者以及有频繁镰状细胞危象病史或血清铁蛋白≥2500的患者,其sFas/sFasL比值升高。接受羟基脲治疗的SCD患者的sFas/sFasL比值低于未接受治疗的患者。sFas/sFasL比值与输血指数、白细胞、hs-CRP、血清铁蛋白和UACR呈正相关。sFas/sFasL在8.75pg/mL时的临界值可区分有无肾病的SCD患者,而在22pg/mL时的临界值能够以高灵敏度和特异性区分有无肺动脉高压风险的SCD患者。
sFas/sFasL比值可被视为SCD患者血管功能障碍的标志物,并且与炎症、铁过载和蛋白尿水平相关。因此,它可能是评估SCD患者肾功能损害的可靠方法。